Skip to main content

High Health Care Utilization, Poor Survival Seen for Over 70s With AML

By Elana Gotkine HealthDay Reporter

Medically reviewed by Carmen Pope, BPharm. Last updated on Aug 19, 2024.

via HealthDay

MONDAY, Aug. 19, 2024 -- Older patients with acute myeloid leukemia (AML) have high health care utilization and poor survival outcomes, according to a study published online Aug. 13 in Hematological Oncology.

Marie Anne-Catherine Neumann, Ph.D., from the University of Cologne in Germany, and colleagues conducted an analysis of 107 consecutive patients with newly diagnosed AML aged 70 years and older treated at an academic tertiary care center in Germany to examine characteristics, outcomes, and health care utilization.

The researchers found that 35, 55, and 10 percent of patients received intensive induction chemotherapy, low-intensity treatment, and either did not receive AML-directed treatment or follow-up ended before initiation of treatment, respectively. Forty-seven percent of patients had at least one intensive care unit admission; specialized palliative care was involved in 43 percent of cases. Overall median survival was 2.5 months, and the rate of one-year overall survival was 16 percent. The median proportion of time spent in the hospital between AML diagnosis and death was 56 percent among patients who died during observation. Normal wards and the intensive care unit were the most common places of death (31 and 28 percent, respectively); death occurred less often in a palliative care unit or at home (14 and 12 percent, respectively).

"The present analysis highlights poor survival outcomes on the one hand and extensive health care utilization on the other hand in patients with AML aged 70 years or older," the authors write.

Several authors disclosed ties to the pharmaceutical industry.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Read this next

Socioeconomic Deprivation Tied to Neurodegeneration in Combat Athletes

THURSDAY, Aug. 14, 2025 -- Athletes experiencing early-life socioeconomic disadvantage may have an increased risk for neurodegeneration from exposure to repetitive head injury...

ADHD Drug Treatment Linked to Reduced Rate of Adverse Outcomes

THURSDAY, Aug. 14, 2025 -- Attention-deficit/hyperactivity disorder (ADHD) drug treatment is associated with reduced rates of adverse outcome events, including suicidality...

2009 to 2023 Saw Increase in Use of Technology, Glycemic Control in Type 1 Diabetes

THURSDAY, Aug. 14, 2025 -- From 2009 to 2023, there was an increase in use of diabetes technology and in glycemic control among youths and adults with type 1 diabetes (T1D)...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.